In the present paper, the biological effects of three different naphthalene diimides (NDIs) G-quadruplex (G4) ligands (H-NDI-Tyr, H-NDI-NMe2, and tetra-NDI-NMe2) were comparatively evaluated to those exerted by RHPS4, a well-characterized telomeric G4-ligand, in an in vitro model of glioblastoma. Data indicated that NDIs were very effective in blocking cell proliferation at nanomolar concentrations, although displaying a lower specificity for telomere targeting compared to RHPS4. In addition, differently from RHPS4, NDIs failed to enhance the effect of ionizing radiation, thus suggesting that additional targets other than telomeres could be involved in the strong NDI-mediated anti-proliferative effects. In order to test telomeric off-target action of NDIs, a panel of genes involved in tumor progression, DNA repair, telomere maintenance, and cell-cycle regulation were evaluated at transcriptional and translational level. Specifically, the compounds were able to cause a marked reduction of TERT and BCL2 amounts as well as to favor the accumulation of proteins involved in cell cycle control. A detailed cytofluorimetric analysis of cell cycle progression by means of bromodeoxyuridine (BrdU) incorporation and staining of phospho-histone H3 indicated that NDIs greatly reduce the progression through S-phase and lead to G1 accumulation of BrdU-positive cells. Taken together, these data indicated that, besides effects on telomeres and oncogenes such as Tert and Bcl2, nanomolar concentrations of NDIs determined a sustained block of cell proliferation by slowing down cell cycle progression during S-phase. In conclusion, our data indicate that NDIs G4-ligands are powerful antiproliferative agents, which act through mechanisms that ultimately lead to altered cell-cycle control.
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Introduction
G-quadruplexes (G4s) are DNA secondary structures that arise spontaneously in guanine-rich genomic regions [1] . These structures are composed of a stack of G-quartets, which are planar assembly of four Hoogsten-bonded guanine bases. Stacks of G-quartets are stabilized by monovalent cations such as K+ and Na+ and under physiological conditions are very stable and resistant to thermal denaturation. The signature motif predicting G4s formation is characterized by four strands of at least three guanines separated by other bases (G ≥ 3N9G ≥ 3N9G ≥ 3N9G ≥ 3, where N is any nitrogen base). Bioinformatics analysis on human genome revealed that G4 sequence motifs are present in gene promoters, gene bodies, and in repetitive DNA such as telomeric DNA [2] . In particular, G4 motifs are often located in oncogene promoters, thus suggesting a function responsible for such conservation during the genome evolution [3] . Although the physiological role of G4s still needs to be deeply understood, different authors proposed this secondary structure as target for cancer therapy [4] [5] [6] . Indeed, G4s can take numerous conformations and different strategies may be adopted to develop compounds with high structural selectivity for a particular G4, making them attractive druggable sites [1, 4, 5, [7] [8] [9] . However, in the last years, a big issue for researchers was the development of therapeutically effective ligands able to bind selectively to their specific targets, minimizing offtarget effects [10] . Indeed, the stabilization of G4 structures determines a number of cellular effects that, in most cases, are directly determined by their localization in the genome. For instance, stabilized G4 in telomeric region hamper telomerase binding to telomeres and induce replication-mediated DNA damage at telomeres, hence determining telomere dysfunction [11] , whereas stabilized G4 in gene promoters or in mRNA may modulate target gene expression [12] [13] [14] [15] .
Nonetheless, other G4 ligand-induced effects are independent or less affected by the region in which the G4 is located. An example is given by the replicative stress caused by physical impediment to polymerase enzymatic activity of G4-stabilized structures [11, 16, 17] . To date, G4 ligands capability to induce the stall of the replication fork was shown in human tumor cells treated with telomestatin [17] whereas BRACO19 was recently proven effective in blocking the activity of translesion Polymerase g, a polymerase involved in the DNA synthesis through G4 structures [16] . Moreover, both RHPS4, Pyridostatin and the ligand 12 459 have been shown to induce transcription and replication-dependent DNA damage resulting in the activation of the ATR/Chk1 pathway and in G2/ M-phase arrest [11, 18, 19] .
In addition, block/delay in the different cell-cycle phases have been reported for the various G4-ligands investigated. Cell cycle effects span from S-phase arrest, as shown for RHPS4 and 2,6-pyridine-dicarboxamide [20] , to G1 arrest as for the Telomestatin derivative Y2H2-6M(4)-oxazole (6OTD) that arrest glioma and glioblastoma stem cells in vitro and in vivo [21] . In addition, G2/M and M-phase arrest was reported for BRACO-19 in U87MG and U251MG [22] and for HXDV, a synthetic analog of Telomestatin, in HEK 293 cells [23] .
In this paper, we tested the biological effectiveness of three different naphthalene diimide (NDI) derivatives (H-NDI-Tyr, H-NDI-NMe2, and tetra-NDINMe2, thereafter named C1, C2 and C6) as inhibitors of cell proliferation in U251MG glioblastoma (GBM) cells. Although NDIs were initially developed for their ability to bind telomeric DNA in vitro, our results show that they caused mild telomere dysfunctions and failed to enhance the effects of ionizing radiation (IR) in GBM cells. Nonetheless, the compounds were able to inhibit the expression of genes such as Bcl2 and hTert [13] and, most importantly, to induce marked perturbations of cell cycle progression, thus indicating them as powerful antiproliferative agents causing remarkable alterations in the control of cell cycle.
Results
The NDI derivatives exert a remarkable cytotoxic activity on GBM In the first step of the study, we comparatively evaluated the cytotoxic activity of the NDI derivatives with respect to RHPS4 in an in vitro GBM cell line (U251MG) and in normal human primary fibroblasts (AG01522). Specifically, a 120-h (5 days) exposure to increasing concentrations (ranging from 0.01 to 1 lM) of NDIs or RHPS4 resulted in a remarkable and concentration-dependent inhibition of cell growth. In particular, the NDI derivatives exerted a superior cytotoxic effect in GBM cells compared to RHPS4, as revealed by the nanomolar values of IC 25 and IC 50 (i.e., concentrations of compounds leading to 25% and 50% inhibition of cell proliferation, respectively), calculated from the dose-response curves ( Fig. 1 ; Table 1 ). In addition, the NDI derivatives exerted a lower cytotoxic effect on AG01522 normal primary fibroblasts than in U251MG, thus suggesting that a good therapeutic window for this class of compounds could exist (Table 1) .
Evaluation of G4 ligand-dependent induction of telomeric alterations
Due to their G4-binding activity, the capability of NDI to induce perturbations in telomere length or architecture was comparatively evaluated with respect to RHPS4. Primarily, we investigated their capability to affect telomere length using centromere-calibrated quantitative fluorescence in situ hybridization (Q-FISH) ( Fig. 2A) . The mean basal values of telomere length were 3.6 and 11.4 T/C% in U251MG and AG01522, respectively (data not shown). Distributions of telomere lengths were clustered in six different groups to compare their frequency, with particular attention to the fraction of very short telomeres (< 5 T/C%). No telomere shortening was observed in cells exposed to NDIs and RHPS4 (both cell lines were treated using the IC 50 calculated for U251MG) as assessed after 120 h of treatment (Fig. 2B,C) .
In order to verify the capability of NDI to induce telomere dysfunctions, the occurrence of telomeric-localized DNA damage was first investigated after the exposure of GBM cells to both IC 25 and IC 50 . Notably, U251MG cells showed a dosedependent induction of DNA damage, which was at least in part localized at telomeric level, as evidenced by the co-localization of 53BP1 with the telomereassociated factor TRF1 (Fig. 2D) . Conversely, telomeric DNA damage induced by RHPS4 was about two times higher than that induced by NDIs at both tested concentrations (Fig. 2E) . On the other hand, no DNA damage induction (both at genomic and telomeric level) was observed in AG01522 cells treated with a concentration of the compounds corresponding to the IC 50 obtained in U251MG cells (Fig. 2F ). To further analyze the effect of NDIs on protein involved in telomere stability and damage, we investigated the binding of the shelterin proteins TRF2 and POT1, and the recruitment of cH2AX at telomeres, by Chromatin Immunoprecipitation (Fig. 2G ). Results showed a significant (P < 0.05) decrease of POT1 for all the NDIs analyzed and a significant diminution in TRF2 levels (P < 0.05) only for RHPS4 (Fig. 2H ). Furthermore, data obtained from the analysis of cH2AX at telomeres demonstrated an increase in telomeric DNA damage with the three NDIs, though a significantly (P < 0.05) higher enrichment in telomeric chromatin upon cH2AX immunoprecipitaton was appreciable only in RHPS4-treated cells (Fig. 2H ), thus indicating that the acridine derivative had a greater specificity for telomeric G4s than NDIs. Overall, these findings would suggest that, as previously reported [13] , other "off-telomere" targets might account for the biological effects exerted by the NDIs. Moreover, to assess whether the NDIs treatment affects telomerase function, hTert gene expression and telomerase activity were evaluated. Although it was previously reported that C2 was able to reduce hTert expression and telomerase activity in SKMel-5 melanoma and H69 lung cancer cell lines [13] , no data are available in the literature regarding the other NDIs. Results indicated that, among NDIs only C1 and C2 were able to reduce hTert expression and telomerase activity (hTert expression was reduced by the 30% and 50% and telomerase activity was reduced by the 50% and 70% after C1 and C2, respectively), whereas C6 did not (Fig. 2I,L) . On the other hand, RHPS4-treated samples showed a 40% reduction of hTert expression and a 50% reduction in telomerase activity confirming previously published data [24] . Interestingly, the exposure of GBM cells to RHPS4 resulted also in a remarkable increase in the amounts of PIN2/TERF1 Interacting Telomerase Inhibitor 1 (PINX1) protein (Fig. 2M,N) , a potent endogenous telomerase inhibitor that plays a pivotal role in telomere length maintenance and chromosome stability [25, 26] . Conversely, PINX1 levels were not significantly affected by NDI treatment (Fig. 2M,N) . These data suggest that although RHPS4 shares with the NDIs (i.e., C1 and C2) the ability to interfere with hTert expression levels and telomerase activity, its superior capability to induce telomere dysfunction with respect to NDIs would rely on additional biological mechanisms, including modulation of PINX1 levels, by which the compounds interferes with telomerase function and hence with telomere homeostasis.
NDIs treatment did not increase cellular response to X-rays
To investigate NDIs radiosensitizing effect on U251MG cells surviving fraction (SF) experiments were performed. In contrast to RHPS4, that shows a potent radiosensitizing effect on GBM cells [27, 28] (Fig. 3A) , NDIs did not increase cell killing up to 6 Gy of X-rays (Fig. 3A ). Data were also confirmed performing longterm growth assays. The heat map in Figure 3B indicates that RHPS4 in combination with 4 Gy of X-rays strongly impaired cell proliferation [evaluated over 21 days as cumulative population doubling level (cPDL)] and the combined effect is much greater than that reported for X-rays and RHPS4 in a single treatment. Conversely, NDIs did not enhance the effect of X-rays in terms of inhibition of cell proliferation (Fig. 3B) .
Further experiments were performed to evaluate DNA repair proficiency after X-ray exposure in the presence or absence of NDIs and RHPS4. Co-immunofluorescence using antibodies directed against the DNA damage markers 53BP1 and cH2AX allowed the analysis of the IR-induced foci (IRIF) that consist in 53BP1 and cH2AX colocalization dots. Data indicated that NDIs did not affect DNA repair in contrast to RHPS4 that interferes with the DNA damage response [27] (Fig. 3C -E). Of note, GBM cells exposed to all the tested ligands were characterized by an increased remaining fraction of cH2AX foci after 6 h, probably due to ligand-dependent, replication stress-mediated DNA damage.
Analysis of a panel of genes harboring putative G4-forming sites and involved in cell transformation, DNA repair and cell cycle regulation Analysis of proteins levels of oncogenes (KIT, MYC, and BCL2) previously reported to be targeted by C2 ligand [13, 29] was performed. Data indicated a slight modulation of Kit and Myc as also confirmed by gene expression (Fig. 4A-C) . On the other side, protein level of the oncogene Bcl2 indicated a significant decrease after the exposure to the drugs, with the ligand C1 inducing the strongest effect (32.1% reduction in protein level compared to untreated cells). Interestingly, RHPS4 induced an opposite effect, with a significant upregulation of BCL2 level (Fig. 4A-C) .
Gene expression levels were assessed for all the ligands and confirmed the dissimilar modulation of Bcl2 expression, highlighting the significant RHPS4-mediated increase of Bcl2 transcript levels (6-fold increase on control level) (Fig. 4C) . With the aim to investigate whether NDIs modulate DNA repair proteins we tested a selected panel of players of the DDR. Most of the protein tested did not show any significant modulation in response to G4 ligands, whereas 53BP1 and cH2AX increase was reported for RHPS4 (data not shown), confirming immunofluorescence data. However, among DDR proteins we found an interesting increase of phospho-ATR (thr1989) levels irrespective of the compound used. Subsequent analysis of the main ATR downstream effector CHK1 in its phosphorylated form (ser345) indicated a strong activation in particular after NDIs treatment (Fig. 4D,G) . Specifically, NDIs were more effective in the phosphorylation of CHK1 whereas higher level of pATR were found in response to RHPS4. Of note, RHPS4 was also able to reduce basal level of CHK1, however this not seems to impact on its phosphorylation. The involvement of ATR and CHK1 suggests the induction of replication stress, likely due to the stall of the replication fork. To investigate the possible occurrence of cell cycle defects, a panel of proteins involved in cell cycle regulation and progression was analyzed (Fig. 4E,F) . NDI treated-cells showed a distinguished modulation in Cyclin E required for the transition from G1 to the S-phase, with the ligand C6 showing the strongest up-regulation. C2 ligand, instead, showed a significant overexpression of Cyclin A compared to controls (Fig. 4H) . NDIs, but not RHPS4, were able to upregulate the levels of p21/CDKN1A (Fig. 4I ). RHPS4 reduced both CDK2 and Proliferating Cell Nuclear Antigen (PCNA) up to the 50% and 40% of control level, respectively. Of note, the latter proteins were not significantly affected by NDIs treatment (Fig. 4H,I ).
NDIs and RHPS4 differently affect cell-cycle progression
On the basis of our biochemical data, the possible occurrence of cell-cycle perturbations in G4 ligandtreated cells was investigated by bromodeoxyuridine (BrdU) pulse and chase experiments. Control cells displayed an evident accumulation in G1 of the BrdU-positive cells at 6-8 h after BrdU washout (Fig. 5A) . On the contrary, NDI-and RHPS4-treated cells showed a delay in the progression of BrdU-positive cells to G1-phase with an evident accumulation only observed after 24 h. In addition, untreated cells re-entered in the S-phase (as BrdUpositive cells) after 24 h from release, whereas for NDI-and RHPS4-treated samples this population was not detected (Fig. 5A ). This data suggests that cells that were in S-phase at the time of the treatment escaped from G2-M and remain arrested in the following G1-phase without moving on to S-phase. To determine how persistent was the G1 blockage observed, we perform a BrdU pulse and fix experiment after 48 h from drugs washout. Data indicated that, differently from NDIs-treated samples that reentered cell cycle as shown by the high percentage of BrdU-labeled cells, RHPS4-treated cells remained totally blocked (Fig. 5B) . With the aim to clarify the progression in M-phase, we tested the status of phospho-Histone-H3 (p-H3) that is phosphorylated at serine 10 during mitosis [30] . To dissect the delay of cell cycle progression after NDIs treatment, we designed a gating strategy based on p-H3 signal vs.
DNA content (Fig. 6A) . Data indicated that only RHPS4 displayed a significant reduction of p-H3 positive cells compared to controls, confirming the general picture of its higher potential to block cell cycle also after drug release (Fig. 6B) . Moreover, we designed a box marker on p-H3 positive cells with a DNA content 4N and a contiguous box with a reduced (< 4N) DNA content. This last box represents cells displaying premature chromosome condensation (PCC) (also known as premature mitosis).
With this cytometric approach we noticed that after 24 h C2 and C6 caused an increase of cells in PCC condition and a further increase of sub-G1 population (Fig. 6C ) that was not detected after C1 and RHPS4 treatment (Fig. 6C) . 
Discussion
Among the plethora of druggable sites proposed for cancer treatment, telomeric G4 have received particular attention in the last years. Data from literature show that ligands able to stabilize telomeric G4, besides affecting cell proliferation when administered as single agent, might display also radiosensitizing properties when combined with IR treatment. Therefore, based on our previous results gained in radioresistant GBM cells [27, 28] , we decided to characterize in detail the cellular effects of three NDIs synthetized in our laboratory. Experiments were performed using U251MG GBM cells, with the purpose of evaluating NDIs capacity to: (a) inhibit glioma growth in single treatment and (b) radiosensitize this highly radioresistant tumor type.
Interestingly, when looking at the antiproliferative effect, we found IC 50 values in the nanomolar concentrations range (180, 75 and 33 nM for C1, C2 and C6, respectively) whereas the IC 50 value calculated for RHPS4 was in the micromolar range [27] . In addition, as previously reported for RHPS4, also NDI IC 50 values were lower for tumor cells compared to primary fibroblasts, representative of human normal tissues. However, a panel of tests for telomere dysfunctionalization, ranging from TIF immunostaining to ChIP assay, showed that the telomere targeting effectiveness of NDIs was always lower compared to that of RHPS4. In particular, RHPS4 was the most effective ligand in the induction of DNA damage at telomeres and ChIP experiments indicated that both TRF2 and POT1 were significantly displaced from telomeres after treatment whereas cH2AX increased, indicating DDR activation. Interestingly, all the ligands induced the displacement of POT1 from telomeres. POT1 detachment from telomeric 3 0 -overhang determines its degradation and may impair the telomerase docking to telomeres [31] suggesting that all the ligands may have a telomerase inhibitory potential by the targeting of the telomerase docking site. Moreover, C1, C2 and RHPS4 determined also the reduction of hTert expression levels and telomerase activity indicating that at least two different mechanisms contributed to telomerase inactivation in U251MG cells. Downregulation of hTert gene was (very likely) determined by the direct stabilization of G4 at the hTert gene promoter [24] . Indeed, hTert promoter holds different G4-forming regions [32] and a direct binding has been shown for other ligands, such as Telomestatin and TMPyP4 [33] . Interestingly, here we report that an additional mechanism of telomerase repression is caused by RHPS4 treatment. Indeed, analysis of PINX1, a telomerase repressor [34] frequently downregulated in cancer [35] [36] [37] and negatively associated with metastasis and prognosis, was upregulated after RHPS4 treatment, indicating that multiple mechanisms may cooperate to repress telomerase activity upon G4 exposure.
Telomere dysfunction has been associated with an increased response to IR [38] [39] [40] . Consequently telomere-and telomerase-targeting drugs may represent a powerful tool to increase radiotherapy outcome in radioresistant cancer treatment [41] . In contrast to RHPS4 [27] , NDIs did not increase U251MG sensitivity to X-rays as shown by SF and long-term proliferation experiments. In this context, analysis of IR-induced DNA damage repair kinetic failed to show any difference between NDIs-treated anduntreated samples, whereas RHPS4 determined a delay in DSB-rejoining [27, 28] . The potent antiproliferative effect of NDIs accompanied by the moderate telomeric specificity and the absence of radiosensitization in U251MG cells opened the way to the search for additional NDIs targets others than telomeres. Of note, NDIs telomere specificity (C2 > C1 > C6) seems to be unlinked from the extent of proliferation inhibition (C6 > C2 > C1), supporting that factors other than telomeres were implicated in U251MG response to NDIs. In fact, it has been previously shown that C2 was able to differently modulate the expression of genes involved in telomere function and cancerrelated mechanisms [13] . For this purpose, we evaluated the amounts of proteins encoded by genes involved in DNA repair, replication stress and cell cycle regulation.
However, we did not find any significant modulation in the amounts of DNA repair factors including both DSBs sensing and repair (i.e., NBN, RAD50, MRE11, DNA-PK, Ku80, 53BP1, cH2AX, BLM, and WRN) (data not shown). Conversely, we found interesting variations in proteins involved in the signaling of replicative stress and in cell cycle regulation. The ATR-CHK1 mediated DNA damage response is generally thought to be the main replication-stress responsive pathway that mediates cellular DNA damage checkpoint responses in S-phase [42] [43] [44] . Our data indicated increased levels of pATR and pCHK1 after treatment with both ligands thus suggesting that also for NDIs a major mechanism for cytotoxicity is related to replication stress occurring during the Sphase. In line with this observation, NDIs prompted the increase in cyclin E and A, suggesting a slowdown of S-phase whereas RHPS4 induced the downregulation of CDK2 and PCNA, indicating an S-phase depletion. Interestingly, significant increase in p21/ CDKN1A level after NDIs treatment may indicate that cells escaping S-phase blockage enter again in the cell cycle and then accumulate in G1. Modulation of genes involved in cell cycle regulation and replicative stress signaling confirmed that the antiproliferative effect observed may be determined by an incorrect progression in the cell cycle and in particular into S-phase. Indeed, a stabilized G4 may represent a physical impediment to replication fork progression, determining critical cell cycle perturbations. In particular, a detailed analysis of G4-ligands-mediated cell cycle effect is restricted to few compounds and results are not univocal, also depending from cell type and experimental setting (e.g., ligand concentration and treatment duration). To date, no data are available on cell cycle effects of NDIs. Conversely, RHPS4 chronic exposure has been reported to lead to replicative stress and damage in S-phase with a consequent delay in the S-G2 transition or even S-phase block in BJ-HELT, Hela [16] , medulloblastoma and high-grade glioma cells or to an increased proportion of G1-phase cells in PSKF-1 central nervous system primitive neuroectodermal cells [45] . In order to check cell cycle progression with particular attention to S and G2/M phase, we performed BrdU incorporation experiments and M-phase analysis through the immunostaining of the phosphorylated form (phopspho-S10) of the histone H3, which is a specific marker of mitosis. We found a strong delay in S-phase for all the ligands analyzed that results in a significant G1 accumulation. However, also in this case, NDIs and RHPS4 behaved differently: the NDI-mediated delay in S-phase was transient and cell recovered S-phase after 48 h from ligands wash-out, whereas RHPS4 treated cells showed a persistent block (up to 48 h) with a total depletion of S-phase cells. Also, analysis of M-phase cells underlines the difference between the two classes of compounds, showing a depletion of M-phase cells after RHPS4 but not after NDIs, indicating that the acridine salt determined a very strong blockage of cell cycle that persisted also after drug washout. In contrast, we observed a fraction of cells engaging PCC after NDIs but not after RHPS4 treatment. Interestingly, PCC correlated with a significant percentage of ipoG1 cells in C2-and C6-treated samples that, of note, were also characterized by the downregulation of the anti-apoptotic factor BCL2 and increased levels of p21/CDKN1A.
Overall, our results indicated that NDIs and RHPS4 induced distinct cellular effects thus underlying the great relevance for an accurate characterization of "target" and "off-target" effects during G4-ligands study and validation. Interestingly, analysis of protein levels and gene expression (in particular for BCL2, Cyclin A and E, CDK2, PCNA, p21/ CDKN1A) indicated a diametrically opposite behavior between the two classes of ligands and suggested a different target spectrum. Indeed, though NDIs and RHSP4 are both able to bind with high affinity G4 DNA, affinity constants obtained by surface plasmon resonance analyses (for htel22 are: 99106 M À1 for RHPS4 and from 79106 M À1 to 3.19105 M À1 for the NDIs [29, [46] [47] [48] ) suggested that the major difference between NDIs and RHPS4 may be related to the G4 selectivity. In this regard, it is well known that G4 can adopt multiple topologies, i.e., parallel, antiparallel and hybrid [49] . Pentacyclic acridine derivative as RHPS4, and a number of its analogues, preferentially binds to anti-parallel and hybrid topologies of human telomeric quadruplex DNA [50, 51] . In contrast, the parallel topology can be selectively stabilized by NDIs [29, 52, 53] .
In conclusion the present paper indicates NDIs as very potent antiproliferative agents as tested in U251MG GBM cells. Among NDIs, C2 was the most interesting agent, able to induce moderate telomere dysfunction, Bcl2 downregulation, ATR-CHK1 DNA damage response, cell cycle slowdown in S-phase coupled with PCC and apoptosis. On the other hand, our data confirmed the very interesting profile of RHPS4 as antiproliferative drug in glioblastoma. In addition to the well-known effects of this pentacyclic acridine compound, here we report also its remarkable ability to upregulate the telomerase inhibitor PINX1, which has been recently reported as a suppressive gene in glioma through its ability to repress telomerase activity and cell invasion and migration [54] .
Materials and methods

Cell lines and culture conditions
Media and supplements for cell culture were purchased from Euroclone (Euroclone, Pero, MI, Italy) and the plasticware was purchased from Corning (Corning Life Sciences, Oneonta, NY, USA). U251MG (Astrocytoma IV WHO grade) cell line, was purchased from Banca Biologica and Cell Factory (Genoa, Italy). AG01522 normal human primary fibroblasts (PD 18-25) were purchased from Coriell Institute (Camden, NJ, USA).
U251MG were routinely maintained in minimum essential medium with Earle's balanced salt solution (MEM/EBSS) supplemented with 10% FBS, 2 mM L-glutamine, 1 mM sodium Pyruvate, 1% non-essential aminoacids, 100 unitsÁmL À1 penicillin and 100 lgÁmL À1 streptomycin. AG01522 were maintained in EMEM/EBSS with 15% FBS, 2 mM L-glutammine, 1% non-essential aminoacids, 100 unitsÁmL À1 penicillin and 100 lgÁmL À1 streptomycin. U251MG was proven to be telomerase positive based on the results from TRAP-assay. All the aforementioned cell lines were maintained at 37°C in a 5% CO2 95% air atmosphere.
Chemical compound and treatments
Tri-and tetra-substituted naphthalene diimide (NDI) ligands, namely H-NDI-NMe1 -C1, H-NDI-NMe2 -C2 and H-NDI-NMe6 -C6, were dissolved in dimethyl sulfoxide (DMSO), as also pentacyclic acridine, 3,11-difluoro-6,8,13-trimethyl-8Hquino[4,3,2-kl]acridinium methosulfate (RHPS4) (kindly provided by Malcolm Stevens, University of Notthingham, Notthingham, UK). The chemical structures of compounds were reported in Figure 7 . The drugs were always added to the cells 24 h after plating. An appropriate volume of DMSO was employed as the negative control. Drugs were freshly prepared from frozen aliquots for each set of experiments.
Sulforhodamine B (SRB) assay
Exponential growing cells were harvested with trypsin-EDTA counted and seeded in 96-well plates at a density of 4000 cells/well. Optimal seeding density was determined to ensure exponential growth during a 5-day assay (120 h). The SRB assay was performed as previously described [55] , with minor modifications. Cell were fixed in 10% cold trichloroacetic acid, incubated at 4°C for 1 h and then washed with deionized water. Cells were stained with 200 lLÁwell À1 of 0.1% SRB (ICN, Asse, Belgium) for 30 min and washed four times with 1% acetic acid. Plates were air dried at room temperature (RT) and stained proteins were solubilized with 200 lL of 10 mM unbuffered Tris base (tris(hydroxymethyl) aminomethane). Optical density was read at 530 nm with a Victor plate-reader (VIC-TOR X3 Multilabel plate reader, PerkinElmer, Waltham, MA, USA). Experiments were repeated four times.
TIF co-immunostaining
Cells were fixed with 4% paraformaldehyde (PFA), permeabilized with 0.5% Triton X-100 and blocked in BSA 1% dissolved in PBS (w/v) as previously described [56] . Samples were then co-immunostained over night (ON) at 4°C, using a rabbit telomeric protein TRF1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) in combination with a mouse monoclonal anti-phospho-histone H2AX antibody (Millipore, Temecula, CA, USA) or an anti-53BP1 antibody (Novus Biologicals, Littleton, CO, USA). After washes in PBS/BSA 1% samples were incubated with the secondary antibody (anti-mouse Alexa 546 and anti-rabbit Alexa 488, Invitrogen, Life Technologies, Carlsbad, CA, USA) for 1 h at 37°C. Finally, slides were washed in PBS/BSA 1%, counterstained with DAPI and analyzed with an Axio-Imager Z2 fluorescent microscope equipped with automatic nucleus capture system (Metacyte, Metasystems, Milano, Italy). The frequency of DNA damage marker foci and TRF1/53BP1 colocalization dots per cell were scored in 100 nuclei in at least two independent experiments.
Collection of chromosome spreads
Chromosome spreads were obtained following incubation in 30 nM calyculin-A (Wako, Osaka, Japan) a protein phosphatase inhibitor that induces chromosome condensation in a cell cycle phase independent manner [57] . Spreads of prematurely condensed chromosomes were prepared following standard procedure consisting of treatment with a hypotonic solution (75 mM KCl) for 20 min at 37°C, followed by fixation in freshly prepared Carnoy solution (3 : 1 v/v methanol/acetic acid). Cells were then dropped onto slides, air dried, and utilized for cytogenetic analysis.
Quantitative fluorescence in situ hybridisation (Q-FISH)
Centromere calibrated Q-FISH staining was performed as previously described [58] . Briefly, 48 h after the seeding, slides were rinsed with PBS at pH 7.5, and fixed in 4% formaldehyde for 2 min. After two rinses in PBS, the slides were incubated in acidified pepsin solution for 10 min, rinsed, and dehydrated through graded alcohols. Slides and probes (Cy3 linked telomeric and chromosome 2 centromeric PNA probe; DAKO Cytomation, Denmark) were co-denatured at 80°C for 3 min and hybridized for 2 h at room temperature in a humidified chamber. After hybridization, slides were washed twice for 15 min in 70% formamide, 10 mM Tris at pH 7.2, and 0.1% BSA, Fig. 7 . Chemical structures of the compounds used throughout the study.
followed by three 5-min washes in 0.1 M Tris at pH 7.5, 0.15 M NaCl, and 0.08% Tween 20. Slides were then dehydrated with an ethanol series, and finally air dried. Slides were counterstained with 4,6-diamidino-2-phenylindole (Sigma Aldrich, St. Louis, MO) in Vectashield (Vector Laboratories, Burlingame, CA, USA). Images were captured at 63X magnification with an Axio Imager Z2 equipped with an automatic metaphase capture system (Metafer, Metasystems) and the telomere size was analyzed with ISIS software (MetaSystems). The software calculates telomere lengths as the ratio between the fluorescence of each telomere signal and the fluorescence of the centromere of chromosome 2, used as the internal reference in each metaphase analyzed. Data were expressed as a percentage (telomere/centromere 9 100 À T/C%) [59, 60] . For each experiment, at least 30 metaphases were analyzed in two independent experiments.
ChIP assay and telomere dot-blot
ChIP analysis was performed as previously described [61] . Briefly 4 9 10 6 cells were used for each experimental point. obtained from a plasmid containing 1.6 kb of TTAGGG repeats labeled with a-32P. The signal was quantified using the IMAGEJ software. For total DNA samples, aliquots corresponding to a 1 : 250 dilution of the amount of lysate used in the immunoprecipitations were processed along with the rest of the samples during the crosslink reversal step. The amount of telomeric DNA immunoprecipitated in each ChIP was calculated based on the signal relative to the corresponding total telomeric DNA input signal, instead for cH2AX data were normalized on the telomeric H3 signal. The ChIP values were presented as the percentage of the total input telomeric DNA, corrected for differences in the number of telomere repeats [62] . Experiments were performed at least in triplicate.
Evaluation of telomerase activity (RTQ-TRAP assay)
Telomerase activity was measured on 1 lg of protein by the SYBR green real-time quantitative telomerase repeat amplification protocol (RTQ-TRAP) assay, which was conducted as described elsewhere [63] with minor modifications. The reaction was performed with protein extracts and anchored return primer mixed with SYBR Green PCR Master Mix (Biorad, Hercules, CA, USA). The reaction was performed using the Agilent AriaMx real-time PCR system (Agilent Technologies, Palo Alto, CA, USA). The threshold cycle values (Ct) were determined from semilog amplification plots (log increase in fluorescence as a function of cycle number) and compared with standard curves generated from serial dilutions of telomerase-positive (tel+) U251MG cell extracts. Each sample was analyzed in triplicate in at least three independent experiments. Telomerase activity was expressed relative to the telomerase-positive (tel+) sample.
Irradiation conditions and combined treatments
X-ray irradiation was performed at RT using a Gilardoni apparatus (250 kV, 6 mA) with a dose rate of 0.53 GyÁmin À1 . NDIs and X-ray combined treatments were performed by treating cells for 120 h with concentrations corresponding to the IC50 and then irradiating with doses comprised between 0.5 and 6 Gy.
Colony-forming assay
To evaluate clonogenic survival, untreated and NDI-treated U251MG cells were irradiated with 0.5-6 Gy of X-ray and then plated at appropriate concentrations in T25 culture flasks in triplicate. After 15 days, cells were fixed/stained with an aqueous solution containing 0.25% (w/v) crystal violet, 70% (v/v) methanol and 3% (v/v) formaldehyde, and they were counted. Only colonies comprised of > 50 cells were included in the quantification. For each treatment, the SF was assessed according to the following formula: SF = number of colonies formed/number of cells seeded. Plating efficiency was represented by the SF in untreated conditions. Results were reported as the mean of three independent experiments. 
Long-term proliferation assessment
Flow cytometric analysis
S-phase progression was evaluated by two different approaches: pulse and chase and pulse and fix methods. The first is aimed to understanding the progression of cells in Sphase at the time of treatment and their possible delay over time. For this purpose, after treatment cells were pulsed 30 min with 10 lM BrdU, then washed and grown in fresh medium and harvested at 2, 4, 6, 8 and 24 h. The second method is aimed to understanding if NDIs have an effect in terms of reduction or block in cell proliferation at longer times from drugs wash-out. To do this, after treatment, NDIs and RHPS4 were washed-out and cells were incubated in fresh medium for 48 h. In the last 30 min, BrdU was added to the medium and then cells were fixed and analyzed. For both the protocols, each sample was fixed, permeabilized, and the histones were dissociated with 2 M HCl as previously described [65] . BrdU-positive cells were detected with an antiBrdU primary antibody diluted 1 : 100 (DAKO Cytomatation) and with an anti-mouse-Alexa488 conjugated diluted 1 : 100 (Invitrogen). Both antibodies were incubated for 1 h RT in the dark. All samples were counterstained with propidium iodide (PI) for DNA/BrdU biparametric analysis. The percentage of cells in mitosis was assessed using a cytometric biparametric analysis of phospho-histone H3 (S10) (Cell Signaling Technology) vs. DNA content. Briefly, cells were detached, washed with PBS, and fixed for 15 min at RT with PFA 4% dissolved in PBS (w/v). Subsequently, cells were permeabilized with 90% methanol and left at À20°C for at least 30 min. After rehydratation with 0.5% BSA/PBS (w/v) and 0.1% Triton, cells were incubated with an Alexa 488-conjugated anti-p-H3 (S10) antibody for 1 h at RT. Finally, cells were counterstained with a solution of propidium iodide/ RNaseA as well as for the cell cycle analysis. The p-H3 positive cells were gated and the relative percentage was calculated by CYTEXPERT software (Beckman Coulter, Inc., San Diego, CA, USA).
